$SLXN

Silexion Therapeutics (SLXN) dosed the first patient in its Phase 2/3 trial of SIL204 for locally advanced pancreatic cancer. The trial combines SIL204 with standard chemotherapy. The study is being conducted at Tel Aviv Sourasky Medical Center and will expand to other sites in Israel and Germany. SIL204 is administered via a dual-route delivery strategy. The company aims to evaluate the potential of SIL204 to improve patient outcomes.

Biotech stocks SLXN, SMMT, IOVA, NTHI rose on Sept 29, 2026, due to positive developments. SLXN surged 30% after preclinical data. SMMT gained 6% from AstraZeneca's $2.0B investment. IOVA rose 34% on raised revenue guidance. NTHI increased 7.59% ahead of FDA meeting.

Silexion Therapeutics Corp (SLXN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 28, 2026, Silexion Therapeutics Corp (“ Silexion ” or the “ Company ”) entered into an inducement offer letter agreement (the “ Inducement Letter ”) with certain holders (each a “ Holder ”) of 3,216,928 of the Com

Biotech stocks SLXN and SMMT rose premarket. SLXN gained on positive preclinical data, while SMMT jumped after a $2B equity investment from AZN. NIVF and QURE declined.

Silexion Therapeutics (SLXN) shares surged 61% after reporting positive preclinical results for SIL204, its lead cancer therapy. The study showed dose-dependent gene silencing in KRAS-driven cancer cells. The company is advancing clinical trials. SLXN has a $1.43M market cap, down 99.27% over the past year. Shares fell 4.57% to $0.25 during regular trading.

Silexion Therapeutics (SLXN) reported positive findings from a study on SIL204, its RNAi candidate for KRAS-driven cancers. The study showed SIL204 utilizes lipoproteins for cellular delivery and potent gene silencing. The company is advancing SIL204 in a Phase 2/3 trial for pancreatic cancer and continues site initiation and patient screening. SLXN's stock is up 1.84% to $0.26.

Silexion Therapeutics Corp (SLXN) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Silexion Therapeutics Reports Positive Preclinical Findings for SIL204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in KRAS-Driven Cancers Translational research demonstrates that SIL204 utilizes native serum lipids to facilitate intracellular delivery

Silexion Therapeutics Corp (SLXN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On September 23, 2026, Silexion Therapeutics Corp (the “ Company ”) reconvened (for the second time) its extraordinary general meeting (the “ Meeting ”), which had originally been scheduled for September 9, 2026 but

Tenon Medical (TNON) repaid $5.16M in notes, strengthening its balance sheet. AEON Biopharma (AEON) reported positive study results for ABP-450. Silexion (SLXN) announced September conference participations. Orchestra BioMed (OBIO) and Indaptus (INDP) also shared updates, with shares rising.

Silexion Therapeutics (NASDAQ: SLXN) reported Q2 2026 results and said its SIL204 program moved into active Phase 2/3 for locally advanced pancreatic cancer. The company received Germany’s BfArM CTA approval and initiated the trial at Tel Aviv Sourasky Medical Center in late July. It also reported preclinical immune-sensitization data and closed a public offering with about $2.5M gross proceeds. Q2 R&D was ~$2.2M and net loss ~$3.6M.